

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



AB

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/605, A61K 38/26, A61P 3/08	A1	(11) International Publication Number: WO 00/34332 (43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/US99/28929 (22) International Filing Date: 7 December 1999 (07.12.99) (30) Priority Data: 09/206,833 7 December 1998 (07.12.98) US 60/111,186 7 December 1998 (07.12.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/206,833 (CON) Filed on 7 December 1998 (07.12.98) (71) Applicants (for all designated States except US): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. [FR/FR]; 51-53, rue du Docteur Blanche, F-75016 Paris (FR). THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND [US/US]; 1430 Tulane Avenue, New Orleans, LA 70112 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DONG, Zheng, Xin [CN/US]; 40 Angelica Drive, Framingham, MA 01701 (US). COY, David, H. [US/US]; 1529 Fourth Street, New Orleans, LA 70130 (US).	(74) Agents: TSAO, Y, Rocky et al.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: GLP-1 ANALOGUES (57) Abstract The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GLP-1 ANALOGUES

5

Background of the Invention

The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.

10

Glucagon-like peptide-1 (7-36) amide (GLP-1) (SEQ ID NO: 1) is synthesized in the intestinal L-cells by tissue-specific post-translational processing of the glucagon precursor pre-proglucagon (Varndell, J.M., et al., J. Histochem Cytochem, 1985:33:1080-6) and is released into the circulation in response to a meal. The plasma concentration of GLP-1 rises from a fasting level of approximately 15 pmol/L to a peak postprandial level of 40 pmol/L. It has been demonstrated that, for a given rise in plasma glucose concentration, the increase in plasma insulin is approximately threefold greater when glucose is administered orally compared with intravenously (Kreymann, B., et al., Lancet 1987:2, 1300-4). This alimentary enhancement of insulin release, known as the incretin effect, is primarily humoral and GLP-1 is now thought to be the most potent physiological incretin in humans. In addition to the insulinotropic effect, GLP-1 suppresses glucagon secretion, delays gastric emptying (Wettergren A., et al., Dig Dis Sci 1993:38:665-73) and may enhance peripheral glucose disposal (D'Alessio, D.A. et al., J. Clin Invest 1994:93:2293-6).

15

20

25

30

35

In 1994, the therapeutic potential of GLP-1 was suggested following the observation that a single subcutaneous (s/c) dose of GLP-1 could completely normalize postprandial glucose levels in patients with non-insulin-dependent diabetes mellitus (NIDDM) (Gutniak, M.K., et al., Diabetes Care 1994:17:1039-44). This effect was thought to be mediated both by increased insulin release and by a reduction in glucagon secretion. Furthermore, an intravenous infusion of GLP-1 has been shown to delay postprandial gastric emptying in patients with NIDDM (Williams, B., et al., J. Clin Endo Metab 1996:81:327-32). Unlike sulfonylureas, the insulinotropic action of GLP-1 is dependent on plasma glucose concentration (Holz, G.G. 4th, et al., Nature 1993:361:362-5). Thus, the loss of GLP-1-mediated insulin release at low plasma glucose concentration protects against severe hypoglycemia.

-2-

This combination of actions gives GLP-1 unique potential therapeutic advantages over other agents currently used to treat NIDDM.

Numerous studies have shown that when given to healthy subjects, GLP-1 potentially influences glycemic levels as well as insulin and glucagon concentrations (Orskov, C, *Diabetologia* 35:701-711, 1992; Holst, J.J., et al., Potential of GLP-1 in diabetes management in *Glucagon III, Handbook of Experimental Pharmacology*, Lefevbre PJ, Ed. Berlin, Springer Verlag, 1996, p. 311-326), effects which are glucose dependent (Kreymann, B., et al., *Lancet* ii: 1300-1304, 1987; Weir, G.C., et al., *Diabetes* 38:338-342, 1989). Moreover, it is also effective in patients with diabetes (Gutniak, M., *N. Engl J Med* 226:1316-1322, 1992; Nathan, D.M., et al., *Diabetes Care* 15:270-276, 1992), normalizing blood glucose levels in type 2 diabetic subjects (Nauck, M.A., et al., *Diabetologia* 36:741-744, 1993), and improving glycemic control in type 1 patients (Creutzfeldt, W.O., et al., *Diabetes Care* 19:580-586, 1996), raising the possibility of its use as a therapeutic agent.

GLP-1 is, however, metabolically unstable, having a plasma half-life ($t_{1/2}$) of only 1-2 min *in vivo*. Exogenously administered GLP-1 is also rapidly degraded (Deacon, C.F., et al., *Diabetes* 44:1126-1131, 1995). This metabolic instability limits the therapeutic potential of native GLP-1. Hence, there is a need for GLP-1 analogues that are more active or are more metabolically stable than native GLP-1.

Summary of the Invention

In one aspect, the present invention is directed to a compound of formula (I),
 $(R^2R^3)-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}-A^{18}-A^{19}-A^{20}-A^{21}-A^{22}-A^{23}-A^{24}-A^{25}-A^{26}-A^{27}-A^{28}-A^{29}-A^{30}-A^{31}-A^{32}-A^{33}-A^{34}-A^{35}-A^{36}-A^{37}-R^1$,

(I)

wherein

A^7 is L-His, Ura, Paa, Pta, D-His, Tyr, 3-Pal, 4-Pal, Hppa, Tma-His, Amp or deleted, provided that when A^7 is Ura, Paa, Pta or Hppa then R^2 and R^3 are deleted;

A^8 is Ala, D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala, Arg or N-Me-Gly;

A^9 is Glu, N-Me-Glu, N-Me-Asp or Asp;

A^{10} is Gly, Acc, Ala, D-Ala, Phe or Aib;

A^{11} is Thr or Ser;

A^{12} is Phe, Acc, Aic, Aib, 3-Pal, 4-Pal, β -Nal, Cha, Trp or X^1 -Phe;


A^{13} is Thr or Ser;

A^{14} is Ser, Thr, Ala or Aib;

-3-

- A¹⁵ is Asp, Ala, D-Asp or Glu;
 A¹⁶ is Val, D-Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala, D-Ala, Tba or Cha;
 A¹⁷ is Ser, Ala, D-Ala, Aib, Acc or Thr;
 A¹⁸ is Ser, Ala, D-Ala, Aib, Acc or Thr;
 5 A¹⁹ is Tyr, D-Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β-Nal, Amp or X¹-Phe;
 A²⁰ is Leu, Ala, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X¹-Phe;
 A²¹ is Glu, Ala or Asp;
 A²² is Gly, Acc, Ala, D-Ala, β-Ala or Aib;
 A²³ is Gln, Asp, Ala, D-Ala, Aib, Acc, Asn or Glu;
 10 A²⁴ is Ala, Aib, Val, Abu, Tle or Acc;
 A²⁵ is Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-NR¹⁰R¹¹)-C(O) or HN-CH((CH₂)_e-X³)-C(O);
 A²⁶ is Lys, Ala, 3-Pal, 4-Pal, Arg, hArg, Orn, Amp, HN-CH((CH₂)_n-NR¹⁰R¹¹)-C(O) or HN-CH((CH₂)_e-X³)-C(O);
 15 A²⁷ is Glu, Ala, D-Ala or Asp;
 A²⁸ is Phe, Ala, Pal, β-Nal, X¹-Phe, Aic, Acc, Aib, Cha or Trp;
 A²⁹ is Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala, Tba or Phe;
 A³⁰ is Ala, Aib, Acc or deleted;
 A³¹ is Trp, Ala, β-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib, Cha, Amp or deleted;
 20 A³² is Leu, Ala, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X¹-Phe, Ala or deleted;
 A³³ is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, X¹-Phe, Tba, Gaba or deleted;
 A³⁴ is Lys, Arg, hArg, Orn, Amp, Gaba, HN-CH((CH₂)_n-NR¹⁰R¹¹)-C(O), HN-CH((CH₂)_e-X³)-C(O) or deleted;
 25 A³⁵ is Gly or deleted;
 A³⁶ is L- or D-Arg, D- or L-Lys, D- or L-hArg, D- or L-Orn, Amp, HN-CH((CH₂)_n-NR¹⁰R¹¹)-C(O), HN-CH((CH₂)_e-X³)-C(O) or deleted;
 A³⁷ is Gly or deleted;
 X¹ for each occurrence is independently selected from the group consisting
 30 of (C₁-C₆)alkyl, OH and halo;
 R¹ is OH, NH₂, (C₁-C₁₂)alkoxy, or NH-X²-CH₂-Z⁰, wherein X² is a (C₁-C₁₂)hydrocarbon moiety, and Z⁰ is H, OH, CO₂H or CONH₂;


-4-



X^3 is or $\text{---C(O)---NHR}^{12}$, wherein X^4 for each occurrence is independently ---C(O)--- , ---NH---C(O)--- or $\text{---CH}_2\text{---}$, and f for each occurrence is independently an integer from 1 to 29;

each of R^2 and R^3 is independently selected from the group consisting of H, (C₁–C₃₀)alkyl, (C₂–C₃₀)alkenyl, phenyl(C₁–C₃₀)alkyl, naphthyl(C₁–C₃₀)alkyl, hydroxy(C₁–C₃₀)alkyl, hydroxy(C₂–C₃₀)alkenyl, hydroxyphenyl(C₁–C₃₀)alkyl, and hydroxynaphthyl(C₁–C₃₀)alkyl; or one of R^2 and R^3 is C(O)X^5 in which X^5 is (C₁–C₃₀)alkyl, (C₂–C₃₀)alkenyl, phenyl(C₁–C₃₀)alkyl, naphthyl(C₁–C₃₀)alkyl, hydroxy(C₁–C₃₀)alkyl, hydroxy(C₂–C₃₀)alkenyl, hydroxyphenyl(C₁–C₃₀)alkyl,



hydroxynaphthyl(C₁–C₃₀)alkyl, $(\text{CH}_3)_2\text{---N} \begin{array}{c} \uparrow \\ \text{---C}^+ \end{array} \text{=N}^+(\text{CH}_3)_2$,



where Y is H or OH, r is 0–4 and q is 0–4;

n for each occurrence is independently an integer from 1–5; and

R^{10} and R^{11} for each occurrence is each independently H, (C₁–C₃₀)alkyl, (C₁–C₃₀)acyl, (C₁–C₃₀)alkylsulfonyl, $\text{---C}((\text{NH})(\text{NH}_2))$ or



R^{11} is H or (C₁–C₃₀)alkyl; and

R^{12} is (C₁–C₃₀)alkyl;

with the proviso that:

(i) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1(7–36, or –37)NH₂ (SEQ ID NOS: 1, 2) or hGLP-1(7–36, or –37)OH (SEQ ID NOS: 3, 4);

-5-

- (ii) a compound of formula (I) is not an analogue of hGLP-1(7-36, or -37)NH₂ (SEQ ID NOS: 1, 2) or hGLP-1(7-36, or -37)OH (SEQ ID NOS: 3, 4) wherein a single position has been substituted by Ala;
- (iii) a compound of formula (I) is not [Lys²⁶(N^E-alkanoyl)]hGLP-1(7-36, or -37)-E (SEQ ID NOS: 5-8), [Lys³⁴(N^E-alkanoyl)]hGLP-1(7-36, or -37)-E (SEQ ID NOS: 9-12), [Lys^{26,34}-bis(N^E-alkanoyl)]hGLP-1(7-36, or -37)-E (SEQ ID NOS: 13-16), [Arg²⁶, Lys³⁴(N^E-alkanoyl)]hGLP-1(8-36, or -37)-E (SEQ ID NOS: 17-20), or [Arg^{26,34}, Lys³⁶(N^E-alkanoyl)]hGLP-1(7-36, or -37)-E, wherein E is -OH or -NH₂ (SEQ ID NOS: 21-24);
- (iv) a compound of formula (I) is not Z¹-hGLP-1(7-36, or -37)-OH, Z¹-hGLP-1(7-36, or -37)-NH₂, where Z¹ is selected from the group consisting of
- (a) [Arg²⁶] (SEQ ID NOS: 25-28), [Arg³⁴] (SEQ ID NOS: 29-32), [Arg^{26,34}] (SEQ ID NOS: 33-36), [Lys³⁶] (SEQ ID NOS: 37-40), [Arg²⁶, Lys³⁶] (SEQ ID NOS: 41-44), [Arg³⁴, Lys³⁶] (SEQ ID NOS: 45-48), [D-Lys³⁶], [Arg³⁶] (SEQ ID NOS: 3,4,1,2), [D-Arg³⁶], [Arg^{26,34}, Lys³⁶] (SEQ ID NOS: 49-52), or [Arg^{26,36}, Lys³⁴] (SEQ ID NOS: 25-28);
- (b) [Asp²¹] (SEQ ID NOS: 53-56);
- (c) at least one of [Aib⁸] (SEQ ID NOS: 57-60), [D-Ala⁸] and [Asp⁹] (SEQ ID NOS: 61-64); and
- (d) [Tyr⁷] (SEQ ID NOS: 65-68), [N-acyl-His⁷] (SEQ ID NOS: 69-72), [N-alkyl-His⁷], [N-acyl-D-His⁷] (SEQ ID NOS: 73-76) or [N-alkyl-D-His⁷];
- (v) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (a) to (d); and
- (vi) a compound of formula (I) is not [N-Me-Ala⁸]hGLP-1(8-36 or -37) (SEQ ID NOS: 75, 78), [Glu¹⁵]hGLP-1(7-36 or -37) (SEQ ID NOS: 79, 80), [Asp²¹]hGLP-1(7-36 or -37) (SEQ ID NOS: 53, 54) or [Phe³¹]hGLP-1(7-36 or -37) (SEQ ID NOS: 81, 82).

A preferred compound of the immediately foregoing compound of formula (I) is where A¹¹ is Thr; A¹³ is Thr; A¹⁴ is Ser, Aib or Ala; A¹⁷ is Ser, Ala, Aib or D-Ala; A¹⁸ is Ser, Ala, Aib or D-Ala; A²¹ is Glu or Ala; A²³ is Gln, Glu, or Ala; and A²⁷ is Glu or Ala; or a pharmaceutically acceptable salt thereof.

A preferred compound of the immediately foregoing compound of formula (I) is where A⁹ is Glu, N-Me-Glu or N-Me-Asp; A¹² is Phe, Acc or Aic; A¹⁶ is Val, D-Val, Acc, Aib, Ala, Tle or D-Ala; A¹⁹ is Tyr, 3-Pal, 4-Pal or D-Tyr; A²⁰ is Leu, Acc, Cha, Ala or Tle; A²⁴ is Ala, Aib or Acc; A²⁵ is Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-


-6-

$\text{CH}((\text{CH}_2)_n\text{-NH-R}^{10})\text{-C(O)}$; A^{28} is Phe or Ala; A^{29} is Ile, Acc or Tle; A^{30} is Ala, Aib or deleted; A^{31} is Trp, Ala, 3-Pal, 4-Pal or deleted; A^{32} is Leu, Acc, Cha, Ala or deleted; A^{33} is Val, Acc, Ala, Gaba, Tle or deleted; or a pharmaceutically acceptable salt thereof.

- 5 A preferred compound of the immediately foregoing compound of formula (I) is where A^8 is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A^{10} is Gly, Ala, D-Ala or Phe; A^{12} is Phe, A6c or A5c; A^{16} is Val, Ala, Tle, A6c, A5c or D-Val; A^{20} is Leu, A6c, A5c, Cha, Ala or Tle; A^{22} is Gly, Aib, β -Ala, L-Ala or D-Ala; A^{24} is Ala or Aib; A^{29} is Ile, A6c, A5c or Tle; A^{32} is Leu, A6c, A5c, Cha, Ala or deleted;
10 A^{33} is Val, A6c, A5c, Ala, Gaba, Tle or deleted; or a pharmaceutically acceptable salt thereof.

A preferred compound of the immediately foregoing compound of formula (I) is where R^1 is OH or NH_2 or a pharmaceutically acceptable salt thereof.

- A preferred compound of the immediately foregoing compound of formula (I)
15 or a pharmaceutically acceptable salt thereof is where R^2 is H and R^3 is ($\text{C}_1\text{-C}_{30}$)alkyl, ($\text{C}_2\text{-C}_{30}$)alkenyl, ($\text{C}_1\text{-C}_{30}$)acyl,



- A most preferred compound of formula (I) is where said compound is
20 $[\text{D-Ala}^8, \text{Ala}^{17,22,23,27}, 3\text{-Pal}^{19,31}, \text{Gaba}^{34}]\text{-GLP-1(7-34)NH}_2$; $[\text{D-Ala}^{8,23,27}, 3\text{-Pal}^{19,31}]\text{hGLP-1(7-35)-NH}_2$; $[\text{Ala}^{18,23,27}, 3\text{-Pal}^{19,31}]\text{hGLP-1(7-35)-NH}_2$ (SEQ ID NO: 83); $[\text{Ala}^{16,23,27}, 3\text{-Pal}^{19,31}]\text{hGLP-1(7-35)-NH}_2$ (SEQ ID NO: 84); $[\text{Ala}^{14,23,27}, 3\text{-Pal}^{19,31}]\text{hGLP-1(7-35)-NH}_2$ (SEQ ID NO: 85); $[\text{Ala}^{22,23,27}, 3\text{-Pal}^{19,31}]\text{hGLP-1(7-35)-NH}_2$ (SEQ ID NO: 86); $[\text{Hppa}^7]\text{hGLP-1(7-36)-NH}_2$ (SEQ ID NO: 87); $[\text{Ala}^{15,23,27}, 3\text{-Pal}^{19,31}]\text{hGLP-1(7-35)-NH}_2$ (SEQ ID NO: 88); $[\text{Ala}^{17,23,27}, 3\text{-Pal}^{19,31}]\text{hGLP-1(7-35)-NH}_2$ (SEQ ID NO: 89); $[\text{Ala}^{22,23,27}, 3\text{-Pal}^{19,31}, \text{Gaba}^{34}]\text{hGLP-1(7-34)-NH}_2$ (SEQ ID NO: 90); $[\text{Ala}^{15,22,23,27}, 3\text{-Pal}^{19,31}, \text{Gaba}^{34}]\text{hGLP-1(7-34)-NH}_2$ (SEQ ID NO: 91); $[\text{Ala}^{17,22,23,27}, 3\text{-Pal}^{19,31}, \text{Gaba}^{34}]\text{hGLP-1(7-34)-NH}_2$ (SEQ ID NO: 92); $[\text{Ala}^{18,22,23,27}, 3\text{-Pal}^{19,31}, \text{Gaba}^{34}]\text{hGLP-1(7-34)-NH}_2$ (SEQ ID NO: 93); $[\text{Ala}^{21,22,23,27}, 3\text{-Pal}^{19,31}, \text{Gaba}^{34}]\text{hGLP-1(7-34)-NH}_2$ (SEQ ID NO: 94); $[\text{Ala}^{22,23,26,27}, 3\text{-Pal}^{19,31}, \text{Gaba}^{34}]\text{hGLP-1(7-34)-NH}_2$
30

-7-

(SEQ ID NO: 95); [Ala^{22,23,27,32}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 96); [Ala^{22,23,26,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 97); [Ala^{22,23,27,31}, 3-Pal¹⁹, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 98); [Ala^{22,23,27,28}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 99); [Ala^{22,23,27,29}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 100); [Ala^{23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 101); [Ala^{20,22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 102); [Ala^{22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 103); [Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 104); [D-Ala¹⁰, Ala^{22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂; [D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}]hGLP-1(7-34)-NH₂; [Ala^{17,23,27}, 3-Pal^{19,26,31}]hGLP-1(7-34)-NH₂ (SEQ ID NO: 105); [D-Ala⁸, Ala¹⁷, 3-Pal^{19,31}]hGLP-1(7-34)-NH₂; [Ala^{17,23,27}, 3-Pal^{19,31}]hGLP-1(7-34)-NH₂ (SEQ ID NO: 106); [D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Tle²⁹]hGLP-1(7-34)-NH₂; [D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Tle¹⁶]hGLP-1(7-34)-NH₂; [D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; [D-Ala²², Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; [Aib⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 107); [D-Ala⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂; [Aib⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂ (SEQ ID NO: 108); [Ala^{17,18,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 109); [Ala^{17,23,27}, 3-Pal^{19,31}, Tle³³, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 110); [Tle¹⁶, Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 111); [N-Me-D-Ala⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂; [Aib⁸, Ala^{17,18,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂ (SEQ ID NO: 112); [Ala^{17,18,22,23,27}, 3-Pal^{19,31}, Tle^{16,20}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 113); [D-Ala⁸, Ala^{17,18,22,23,27}, 3-Pal^{19,31}, Tle¹⁶, Gaba³⁴]hGLP-1(7-34)-NH₂; [D-Ala^{8,22}, Ala^{17,18,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; [D-Ala^{8,18}, Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; [D-Ala^{8,17}, Ala^{18,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; or [D-Ala⁸, Ala^{17,18,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; or a pharmaceutically acceptable salt thereof.

Another most preferred compound of formula (I) is wherein said compound is

[Aib⁸, A6c³²]hGLP-1(7-36)NH₂ (SEQ ID NO: 114); [A6c^{20,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 115); [Aib⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 116); [(Tma-His)⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 117); [A6c⁸]hGLP-1(8-36)-NH₂ (SEQ ID NO: 118); [A6c⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 119); [A6c^{16,20}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 120); [A6c^{29,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 121); [A6c²⁰, Aib²⁴]hGLP-1(7-36)-NH₂ (SEQ ID NO: 122); [Aib²⁴, A6c^{29,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 123);


-8-

[A6c^{18,29,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 124); [Ura⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 125); [Paa⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 126); [Pta⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 127); [N-Me-Ala⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 128); [N-Me-Ala⁸]hGLP-1(8-36)-NH₂; (SEQ ID NO.) [N-Me-D-Ala⁸]hGLP-1(7-36)-NH₂; [N-Me-D-Ala⁸]hGLP-1(8-36)-NH₂; [N-Me-Gly⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 129); [A5c⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 130); [N-Me-Glu⁹]hGLP-1(7-36)-NH₂ (SEQ ID NO: 131); [A5c⁸, A6c^{20,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 132); [Aib⁸, A6c³²]hGLP-1(7-36)-NH₂ (SEQ ID NO: 133); [Aib^{8,25}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 134); [Aib^{8,24}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 135); [Aib^{8,30}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 136); [Aib⁸, Cha²⁰]hGLP-1(7-36)-NH₂ (SEQ ID NO: 137); [Aib⁸, Cha³²]hGLP-1(7-36)-NH₂ (SEQ ID NO: 138); [Aib⁸, Glu²³]hGLP-1(7-36)-NH₂ (SEQ ID NO: 139); [Aib⁸, A6c²⁰]hGLP-1(7-36)-NH₂ (SEQ ID NO: 140); [Aib⁸, A6c^{20,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 141); [Aib^{8,22}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 142); [Aib⁸, β-Ala²²]hGLP-1(7-36)-NH₂ (SEQ ID NO: 143); [Aib⁸, Lys²⁵]hGLP-1(7-36)-NH₂ (SEQ ID NO: 144); [Aib⁸, A6c¹²]hGLP-1(7-36)-NH₂ (SEQ ID NO: 145); [Aib⁸, A6c²⁹]hGLP-1(7-36)-NH₂ (SEQ ID NO: 146); [Aib⁸, A6c³³]hGLP-1(7-36)-NH₂ (SEQ ID NO: 147); [Aib^{8,14}]hGLP-1(7-36)NH₂ (SEQ ID NO: 148); [Aib^{8,18}]hGLP-1(7-36)NH₂ (SEQ ID NO: 149); or [Aib^{8,17}]hGLP-1(7-36)NH₂ (SEQ ID NO: 150); or a pharmaceutically acceptable salt thereof. In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.


In still another aspect, the present invention provides a method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) as defined hereinabove or a pharmaceutically acceptable salt thereof.

In yet a further aspect, this invention provides a method of treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease, renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, hypertension, and disorders wherein the reduction of food intake is desired, in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) as


-10-




represented by the following structure: . What is meant by Lys(N^F-(2-(4-alkyl-1-piperazine)-acetyl)) is represented by the following



structure: . What is meant by Asp(1-(4-alkyl-piperazine)) is represented by the following



5 structure: . What is meant by Asp(1-alkylamino)



is represented by the following structure: . The variable n in the foregoing structures is 1 to 30.

The full names for other abbreviations used herein are as follows: Boc for t-butyloxycarbonyl, HF for hydrogen fluoride, Fm for formyl, Xan for xanthyl, Bzl for benzyl, Tos for tosyl, DNP for 2,4-dinitrophenyl, DMF for dimethylformamide, DCM for dichloromethane, HBTU for 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate, DIEA for diisopropylethylamine, HOAc for acetic acid, TFA for trifluoroacetic acid, 2ClZ for 2-chlorobenzyloxycarbonyl and OcHex for O-cyclohexyl.

15 A peptide of this invention is also denoted herein by another format, e.g., [A5c⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 130), with the substituted amino acids from the natural sequence placed between the set of brackets (e.g., A5c⁸ for Ala⁸ in

- hGLP-1). The abbreviation GLP-1 means glucagon-like peptide-1, and hGLP-1 means human glucagon-like peptide-1. The numbers between the parentheses refer to the number of amino acids present in the peptide (e.g., hGLP-1(7-36) (SEQ ID NO: 3) is amino acids 7 through 36 of the peptide sequence for human GLP-1).
- 5 The sequence for hGLP-1(7-37) (SEQ ID NO: 4) is listed in Mojsov, S., Int. J. Peptide Protein Res., 40, 1992, pp. 333-342. The designation "NH₂" in hGLP-1(7-36)NH₂ (SEQ ID NO: 1) indicates that the C-terminus of the peptide is amidated. hGLP-1(7-36) (SEQ ID NO: 2) means that the C-terminus is the free acid.

Detailed Description

- 10 The peptides of this invention can be prepared by standard solid phase peptide synthesis. See, e.g., Stewart, J.M., et al., Solid Phase Synthesis (Pierce Chemical Co., 2d ed. 1984). The substituents R² and R³ of the above generic formula can be attached to the free amine of the N-terminal amino acid by standard methods known in the art. For example, alkyl groups, e.g., (C₁-C₃₀)alkyl, can be
- 15 attached using reductive alkylation. Hydroxyalkyl groups, e.g., (C₁-C₃₀)hydroxyalkyl, can also be attached using reductive alkylation wherein the free hydroxy group is protected with a t-butyl ester. Acyl groups, e.g., COE¹, may be attached by coupling the free acid, e.g., E¹COOH, to the free amine of the N-terminal amino acid by mixing the completed resin with 3 molar equivalents of both
- 20 the free acid and diisopropylcarbodiimide in methylene chloride for one hour. If the free acid contains a free hydroxy group, e.g., p-hydroxyphenylpropionic acid, then the coupling should be performed with an additional 3 molar equivalents of HOBt.

- When R¹ is NH-X²-CH₂-CONH₂ (i.e., Z⁰=CONH₂), the synthesis of the peptide starts with BocHN-X²-CH₂-COOH which is coupled to the MBHA resin. If R¹
- 25 is NH-X²-CH₂-COOH (i.e., Z⁰=COOH) the synthesis of the peptide starts with BocHN-X²-CH₂-COOH which is coupled to PAM resin.

The following describes a synthetic method for making a peptide of this invention, which method is well-known to those skilled in the art. Other methods are also known to those skilled in the art.

- 30 Benzhydrylamine-polystyrene resin (Advanced ChemTech, Inc., Louisville, KY) (0.9 g, 0.3 mmole) in the chloride ion form is placed in a reaction vessel of an Advanced ChemTech Peptide Synthesizer Model 200 programmed to perform the following reaction cycle: (a) methylene chloride; (b) 33% trifluoroacetic acid in

-12-

methylene chloride (2 times for 1 and 15 min each); (c) methylene chloride; (d) ethanol; (e) methylene chloride; (f) 10% diisopropylethylamine in methylene chloride.

The neutralized resin is stirred with Boc-protected amino acid which is to be the C-terminal amino acid of the desired peptide to be synthesized and
5 diisopropylcarbodiimide (3 mmole each) in methylene chloride for 1 hour and the resulting amino acid resin is then cycled through steps (a) through (f) in the above wash program. The other amino acids (3 mmol) of the desired peptide are then coupled successively by the same procedure. The finished peptide is cleaved from the resin by mixing it with anisole (5 ml), dithiothreitol (100 mg) and anhydrous
10 hydrogen fluoride (35 ml) at about 0 °C and stirring it for about 45 min. Excess hydrogen fluoride is evaporated rapidly under a stream of dry nitrogen and free peptide precipitated and washed with ether. The crude peptide is then dissolved in a minimum volume of dilute acetic acid and eluted on a column (2.5 x 25 cm) of VYDAC® octadecylsilane silica (10 mM) and eluted with a linear gradient of 20-60%
15 acetonitrile over about 1 h in 0.1% trifluoroacetic acid in water. Fractions are examined by thin layer chromatography and analytical high performance liquid chromatography (40-70% B at 1%/min, solution B is 80% acetonitrile/water containing 0.1% TFA) and pooled to give maximum purity rather than yield. Repeated lyophilization of the solution from water gives the product as a white,
20 fluffy powder.

The product peptide is analyzed by HPLC. Amino acid analysis of an acid hydrolysate of the product peptide can confirm the composition of the peptide. Laser desorption MS is used to determine the molecular weight of the peptide.

The protected amino acid 1-[N-tert-butoxycarbonyl-amino]-1-cyclohexane-
25 carboxylic acid (Boc-A6c-OH) was synthesized as follows. 19.1 g (0.133 mol) of 1-amino-1-cyclohexanecarboxylic acid (Acros Organics, Fisher Scientific, Pittsburgh, PA) was dissolved in 200 ml of dioxane and 100 ml of water. To it was added 67 ml of 2N NaOH. The solution was cooled in an ice-water bath. 32.0 g (0.147 mol) of di-tert-butyl-dicarbonate was added to this solution. The reaction mixture was
30 stirred overnight at room temperature. Dioxane was then removed under reduced pressure. 200 ml of ethyl acetate was added to the remaining aqueous solution. The mixture was cooled in an ice-water bath. The pH of the aqueous layer was adjusted to about 3 by adding 4N HCl. The organic layer was separated. The aqueous layer was extracted with ethyl acetate (1 x 100 ml). The two organic

-13-

layers were combined and washed with water (2 x 150 ml), dried over anhydrous MgSO_4 , filtered, and concentrated to dryness under reduced pressure. The residue was recrystallized in ethyl acetate/hexanes. 9.2 g of the pure product was obtained. 29% yield.

5 Boc-A5c-OH was synthesized in an analogous manner to that of Boc-A6c-OH. Other protected Acc amino acids can be prepared in an analogous manner by a person of ordinary skill in the art as enabled by the teachings herein.

10 In the synthesis of a peptide of this invention containing A5c, A6c and/or Aib, the coupling time is about 2 hrs. for these residues and the residue immediately following them. For the synthesis of [Tma-His⁷]hGLP-1(7-36)NH₂ (SEQ ID NO: 117), HBTU (2 mmol) and DIEA (1.0 ml) in 4 ml DMF were used to react with the N-terminal free amine of the peptide-resin in the last coupling reaction; the coupling time is about 2 hours.

15 The full names for the abbreviations used above are as follows: Boc for t-butyloxycarbonyl, HF for hydrogen fluoride, Fm for formyl, Xan for xanthyl, Bzl for benzyl, Tos for tosyl, DNP for 2,4-dinitrophenyl, DMF for dimethylformamide, DCM for dichloromethane, HBTU for 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate, DIEA for diisopropylethylamine, HOAc for acetic acid, TFA for trifluoroacetic acid, 2ClZ for 2-chlorobenzyloxycarbonyl, 2BrZ for 2-bromobenzyloxycarbonyl and OcHex for O-cyclohexyl.

20 The substituents R² and R³ of the above generic formula can be attached to the free amine of the N-terminal amino acid by standard methods known in the art. For example, alkyl groups, e.g., (C₁-C₃₀)alkyl, may be attached using reductive alkylation. Hydroxyalkyl groups, e.g., (C₁-C₃₀)hydroxyalkyl, can also be attached using reductive alkylation wherein the free hydroxy group is protected with a t-butyl ester. Acyl groups, e.g., COX¹, can be attached by coupling the free acid, e.g., X¹COOH, to the free amine of the N-terminal amino acid by mixing the completed resin with 3 molar equivalents of both the free acid and diisopropylcarbodiimide in methylene chloride for about one hour. If the free acid contains a free hydroxy group, e.g., p-hydroxyphenylpropionic acid, then the coupling should be performed with an additional 3 molar equivalents of HOBt.

30 A compound of the present invention can be tested for activity as a GLP-1 binding compound according to the following procedure.

Cell Culture:

-14-

RIN 5F rat insulinoma cells (ATCC-# CRL-2058, American Type Culture Collection, Manassas, VA), expressing the GLP-1 receptor, were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum, and maintained at about 37 °C in a humidified atmosphere of 5% CO₂/95% air.

5 Radioligand Binding:

Membranes were prepared for radioligand binding studies by homogenization of the RIN cells in 20 ml of ice-cold 50 mM Tris-HCl with a Brinkman Polytron (Westbury, NY) (setting 6, 15 sec). The homogenates were washed twice by centrifugation (39,000 g / 10 min), and the final pellets were re-suspended in 50 mM Tris-HCl, containing 2.5 mM MgCl₂, 0.1 mg/ml bacitracin (Sigma Chemical, St. Louis, MO), and 0.1% BSA. For assay, aliquots (0.4 ml) were incubated with 0.05 nM [¹²⁵I]GLP-1(7-36) (SEQ ID NO: 151) (~2200 Ci/mmol, New England Nuclear, Boston, MA), with and without 0.05 ml of unlabeled competing test peptides. After a 100 min incubation (25 °C), the bound [¹²⁵I]GLP-1(7-36) (SEQ ID NO: 151) was separated from the free by rapid filtration through GF/C filters (Brandel, Gaithersburg, MD), which had been previously soaked in 0.5% polyethyleneimine. The filters were then washed three times with 5 ml aliquots of ice-cold 50 mM Tris-HCl, and the bound radioactivity trapped on the filters was counted by gamma spectrometry (Wallac LKB, Gaithersburg, MD). Specific binding was defined as the total [¹²⁵I]GLP-1(7-36) (SEQ ID NO: 151) bound minus that bound in the presence of 1000 nM GLP1(7-36) (SEQ ID NO: 3) (Bachem, Torrence, CA).

The peptides of this invention can be provided in the form of pharmaceutically acceptable salts. Examples of such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids). A typical method of making a salt of a peptide of the present invention is well known in the art and can be accomplished by standard methods of salt exchange. Accordingly, the TFA salt of a peptide of the present invention (the TFA salt results from the purification of the peptide by using preparative HPLC, eluting with TFA containing buffer solutions) can be converted into another salt, such as an acetate salt by dissolving the peptide in a small

amount of 0.25 N acetic acid aqueous solution. The resulting solution is applied to a semi-prep HPLC column (Zorbax, 300 SB, C-8). The column is eluted with (1) 0.1N ammonium acetate aqueous solution for 0.5 hrs., (2) 0.25N acetic acid aqueous solution 0.5 hrs. and (3) a linear gradient (20% to 100% of solution B over 30 min.)
5 at a flow rate of 4 ml/min (solution A is 0.25N acetic acid aqueous solution; solution B is 0.25N acetic acid in acetonitrile/water, 80:20). The fractions containing the peptide are collected and lyophilized to dryness.

As is well known to those skilled in the art, the known and potential uses of GLP-1 is varied and multitudinous [See, Todd, J.F., et al., Clinical Science, 1998,
10 95, pp. 325-329; and Todd, J.F. et al., European Journal of Clinical Investigation, 1997, 27, pp.533-536]. Thus, the administration of the compounds of this invention for purposes of eliciting an agonist effect can have the same effects and uses as GLP-1 itself. These varied uses of GLP-1 may be summarized as follows, treatment of: Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of
15 the airway, metabolic disorder, arthritis, osteoporosis, central nervous system diseases, restenosis and neurodegenerative diseases. GLP-1 analogues of the present invention that elicit an antagonist effect from a subject can be used for treating the following: hypoglycemia and malabsorption syndrome associated with gastroectomy or small bowel resection.

20 Accordingly, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of formula (I) in association with a pharmaceutically acceptable carrier or diluent.

The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such
25 that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. In general, an effective dosage for the activities of this invention is in the range of 1×10^{-7} to 200 mg/kg/day, preferably 1×10^{-4} to 100 mg/kg/day, which can be administered as a single dose or divided into multiple doses.

30 The compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.

-16-

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.

Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.

Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax.

Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.

Further, a compound of this invention can be administered in a sustained release composition such as those described in the following patents and patent applications. U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester. U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a bioactive agent in a gelable form. U.S.


-17-

Application No. 08/929,363 filed September 9, 1997, teaches polymeric sustained release compositions comprising a bioactive agent and chitosan. U.S. Application No. 08/740,778 filed November 1, 1996, teaches sustained release compositions comprising a bioactive agent and cyclodextrin. U.S. Application No. 09/015,394 filed 5 January 29, 1998, teaches absorbable sustained release compositions of a bioactive agent. U.S. Application No. 09/121,653 filed July 23, 1998, teaches a process for making microparticles comprising a therapeutic agent such as a peptide in an oil-in-water process. U.S. Application No. 09/131,472 filed August 10, 1998, teaches complexes comprising a therapeutic agent such as a peptide and a 10 phosphorylated polymer. U.S. Application No. 09/184,413 filed November 2, 1998, teaches complexes comprising a therapeutic agent such as a peptide and a polymer bearing a non-polymerizable lactone. The teachings of the foregoing patents and applications are incorporated herein by reference.

Unless defined otherwise, all technical and scientific terms used herein have 15 the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications, patent applications, patents and other references mentioned herein are incorporated by reference.

The following examples describe synthetic methods for making a peptide of this invention, which methods are well-known to those skilled in the art. Other 20 methods are also known to those skilled in the art. The examples are provided for the purpose of illustration and is not meant to limit the scope of the present invention in any manner.

Example 1



25 Benzhydrylamine-polystyrene resin (Advanced ChemTech, Inc. Louisville, KY) (0.9 g, 0.3 mmole) in the chloride ion form was placed in a reaction vessel of an Advanced ChemTech peptide synthesizer Model 200 programmed to perform the following reaction cycle: (a) methylene chloride; (b) 33% trifluoroacetic acid in methylene chloride (2 times for 1 and 15 min each); (c) methylene chloride; (d) 30 ethanol; (e) methylene chloride; (f) 10% diisopropylethylamine in methylene chloride.

The neutralized resin was stirred with Boc-Gaba and diisopropylcarbodiimide (3 mmole each) in methylene chloride for 1 hour and the resulting amino acid resin was then cycled through steps (a) to (f) in the above wash program. The following amino acids (3 mmole) were then coupled

-18-

successively by the same procedure: Boc-Val, Boc-Leu, Boc-3-Pal, Boc-Ala, Boc-Ile, Boc-Phe, Boc-Ala, Boc-Lys(2-Cl-Z), Boc-Ala, Boc-Ala, Boc-Ala, Boc-Ala, Boc-Glu(Bzl), Boc-Leu, Boc-3-Pal, Boc-Ser(Bzl), Boc-Ala, Boc-Val, Boc-Asp(Bzl), Boc-Ser(Bzl), Boc-Thr(Bzl), Boc-Phe, Boc-Thr(Bzl), Boc-Gly, Boc-Glu(Bzl), Boc-D-Ala, Boc-His(Bom).

The resin with the completed peptide sequence was mixed with anisole (5 ml), dithiothreitol (100 mg) and anhydrous hydrogen fluoride (35 ml) at about 0 °C and stirred for about 45 min. Excess hydrogen fluoride was evaporated rapidly under a stream of dry nitrogen and free peptide precipitated and washed with ether.

The crude peptide was then dissolved in a minimum volume of dilute acetic acid and eluted on a column (2.5 x 25 cm) of VYDAC® octadecylsilane silica (10 mM) and eluted with a linear gradient of 20-60% acetonitrile over about 1 h in 0.1% trifluoroacetic acid in water. Fractions were examined by thin layer chromatography and analytical high performance liquid chromatography (40-70% B at 1%/min; r.t.: 14.1 min) and pooled to give maximum purity rather than yield. Repeated lyophilization of the solution from water gives the product (49.9 mg) as a white, fluffy powder.

The product was found to be homogeneous by HPLC and tlc. Amino acid analysis of an acid hydrolysate confirms the composition of the peptide. Laser desorption MS gave a MW of 2880 (Calc. M+H 2873).

Example 2

Synthesis of Peptide Lower-Alkylamides

Peptides are assembled on O-benzyl-polystyrene resin (often referred to as Merrifield resin) using the Boc amino acid protocol described in Example 1, except that Asp and Glu amino acid carboxyl side-chains are protected with an Fm (fluorenylmethyl ester) group. Completed peptide-resins are suspended in dilute DMF solutions of an appropriate lower alkylamine (such as ethylamine, propylamine, phenethylamine, 1,2-diaminoethane, etc.) and stirred at about 60 °C (for about 18 hrs) whereupon filtration, removal of solvents under reduced pressure and trituration of cleaved peptide oil with ether gives a solid, protected alkylamide peptide. This is then subjected to HF cleavage to remove additional side chain protecting groups and HPLC purification as described in Example 1.

Examples 3-5

Examples 3-5 can be synthesized substantially according to the procedure described in Example 1 using the appropriate protected amino acids to yield the noted peptides.

5 Example 3: [Aib⁸, D-Ala¹⁷, Ala^{18,22,23,27}, 3-Pal^{19,31}, Tle¹⁶, Gaba³⁴]-GLP-1(7-34)NH₂

Example 4: [Aib⁸, D-Ala¹⁷, Ala^{22,23,27}, 3-Pal^{19,31}, Tle¹⁶]-GLP-1(7-33)NH₂

Example 5: [Aib⁸, D-Ala¹⁷, Ala^{22,23,27}, 3-Pal^{19,31}, Tle^{16,20}]-GLP-1(7-33)NH₂

Examples 6-51

10 Examples 6-51 were made substantially according to the procedure described for Example 1 but using the appropriate protected amino acid to yield the noted peptide. MS were obtained by laser desorption MS (NA means not available).

Example 6: [D-Ala^{8,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂; MS = 2971.0; Calc. MW = 2974.4.

15 Example 7: [Ala^{18,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 83); MS = 2954.4; Calc. MW = 2958.4.

Example 8: [Ala^{16,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 84); MS = 2943.0; Calc. MW = 2946.3.

Example 9: [Ala^{14,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 85); MS = 2956.0; Calc. MW = 2958.4.

20 Example 10: [Ala^{22,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 86); MS = 2981.0; Calc. MW = 2988.4.

Example 11: [Hppa⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 87); MS = NA

Example 12: [Ala^{15,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 88); MS = 2928.0; Calc. MW = 2930.4.

25 Example 13: [Ala^{17,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 89); MS = 2955.0; Calc. MW = 2958.4.

Example 14: [Ala^{22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 90); MS = 2896.0; Calc. MW = 2888.3.

30 Example 15: [Ala^{15,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 91); MS = 2852.0; Calc. MW = 2844.3.

Example 16: [Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 92); MS = 2880.0; Calc. MW = 2872.3.

Example 17: [Ala^{18,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 93); MS = 2870.0; Calc. MW = 2872.3.

- Example 18: [Ala^{21,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 94); MS = NA.
- Example 19: [Ala^{22,23,26,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 95); MS = 2832.0; Calc. MW = 2831.2.
- 5 Example 20: [Ala^{22,23,27,32}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 96); MS = 2855.0; Calc. MW = 2846.2.
- Example 21: [Ala^{22,23,26,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 97); MS = 2729.0; Calc. MW = 2732.0.
- Example 22: [Ala^{22,23,27,31}, 3-Pal¹⁹, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 98);
- 10 MS = 2711.6; Calc. MW = 2712.0.
- Example 23: [Ala^{22,23,27,28}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 99); MS = 2712.0; Calc. MW = 2713.0.
- Example 24: [Ala^{22,23,27,29}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 100); MS = 2746.9; Calc. MW = 2747.1.
- 15 Example 25: [Ala^{23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 101); MS = 2777.0; Calc. MW = 2,775.1.
- Example 26: [Ala^{20,22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 102); MS = 2742.0; Calc. MW = 2747.1.
- Example 27: [Ala^{22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 103);
- 20 MS = 2786.7; Calc. MW = 2789.1.
- Example 28: [Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 104); MS = 2771.0; Calc. MW = 2773.1.
- Example 29: [D-Ala¹⁰, Ala^{22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂; MS = 2802.0; Calc. MW = 2803.2.
- 25 Example 30: [D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}]hGLP-1(7-34)-NH₂; MS = 2905.0; Calc. MW = 2901.3.
- Example 31: [Ala^{17,23,27}, 3-Pal^{19,26,31}]hGLP-1(7-34)-NH₂ (SEQ ID NO: 105); MS = 2920.0; Calc. MW = 2921.3.
- Example 32: [D-Ala⁸, Ala¹⁷, 3-Pal^{19,31}]hGLP-1(7-34)-NH₂; MS = 2908.0 (Na⁺ salt);
- 30 Calc. MW = 2885.3.
- Example 33: [Ala^{17,23,27}, 3-Pal^{19,31}]hGLP-1(7-34)-NH₂ (SEQ ID NO: 106); MS = 2907.0; Calc. MW = 2901.3.
- Example 34: [D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Tle²⁹]hGLP-1(7-34)-NH₂; MS = 2906.0; Calc. MW = 2901.3.

-21-

- Example 35: [D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Tle¹⁶]hGLP-1(7-34)-NH₂; MS = 2914.0; Calc. MW = 2915.4.
- Example 36: [D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; MS = 2856.8; Calc. MW = 2858.2.
- 5 Example 37: [D-Ala²², Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; MS = 2871.0; Calc. MW = 2872.3.
- Example 38: [Aib⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 107); MS = 2875.0; Calc. MW = 2872.3.
- Example 39: [D-Ala⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂; MS = 2786.0; Calc. MW = 2787.2.
- 10 Example 40: [Aib⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂ (SEQ ID NO: 108); MS = 2800.0; Calc. MW = 2801.2.
- Example 41: [Ala^{17,18,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 109); MS = 2842.5; Calc. MW = 2842.2.
- 15 Example 42: [Ala^{17,23,27}, 3-Pal^{19,31}, Tle³³, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 110); MS = 2871.0; Calc. MW = 2872.3.
- Example 43: [Tle¹⁶, Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 111); MS = 2870.0; Calc. MW = 2872.3.
- Example 44: [N-Me-D-Ala⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂; MS = 2795.0; Calc. MW = 2801.2.
- 20 Example 45: [Aib⁸, Ala^{17,18,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂ (SEQ ID NO: 112); MS = 2784.2; Calc. MW = 2785.2.
- Example 46: [Ala^{17,18,22,23,27}, 3-Pal^{19,31}, Tle^{16,20}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 113); MS = 2871.9; Calc. MW = 2870.3.
- 25 Example 47: [D-Ala⁸, Ala^{17,18,22,23,27}, 3-Pal^{19,31}, Tle¹⁶, Gaba³⁴]hGLP-1(7-34)-NH₂; MS = 2870.0; Calc. MW = 2870.3.
- Example 48: [D-Ala^{8,22}, Ala^{17,18,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; MS = 2856.3; Calc. MW = 2856.3.
- Example 49: [D-Ala^{8,18}, Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; MS = NA.
- 30 Example 50: [D-Ala^{8,17}, Ala^{18,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; MS = NA.
- Example 51: [D-Ala⁸, Ala^{17,18,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; MS = 2861.6; Calc. MW = 2856.3.

-22-

Example 52

[Aib⁸, A6c³²]hGLP-1(7-36)NH₂ (SEQ ID NO: 114)

The title peptide was synthesized on an Applied Biosystems (Foster City, CA) model 430A peptide synthesizer which was modified to do accelerated Boc-chemistry solid phase peptide synthesis. See Schnolzer, et al., Int. J. Peptide Protein Res., 40:180 (1992). 4-Methylbenzhydrylamine (MBHA) resin (Peninsula, Belmont, CA) with the substitution of 0.91 mmol/g was used. The Boc amino acids (Bachem, CA, Torrance, CA; Nova Biochem., LaJolla, CA) were used with the following side chain protection: Boc-Ala-OH, Boc-Arg(Tos)-OH, Boc-Asp(OcHex)-OH, Boc-Tyr(2BrZ)-OH, Boc-His(DNP)-OH, Boc-Val-OH, Boc-Leu-OH, Boc-Gly-OH, Boc-Gln-OH, Boc-Ile-OH, Boc-Lys(2ClZ)-OH, Boc-Thr(Bzl)-OH, Boc-A6c-OH, Ser(Bzl)-OH, Boc-Phe-OH, Boc-Aib-OH, Boc-Glu(OcHex)-OH and Boc-Trp(Fm)-OH. The synthesis was carried out on a 0.20 mmol scale. The Boc groups were removed by treatment with 100% TFA for 2 x 1 min. Boc amino acids (2.5 mmol) were pre-activated with HBTU (2.0 mmol) and DIEA (1.0 ml) in 4 ml of DMF and were coupled without prior neutralization of the peptide-resin TFA salt. Coupling times were about 5 min except for the Boc-Aib-OH and Boc-A6c-OH residues and the following residues, Boc-Trp(Fm)-OH and Boc-His(DNP)-OH wherein the coupling times were about 2 hours.

At the end of the assembly of the peptide chain, the resin was treated with a solution of 20% mercaptoethanol/10% DIEA in DMF for 2 x 30 min to remove the DNP group on the His side chain. The N-terminal Boc group was then removed by treatment with 100% TFA for 2 x 2 min. After neutralization of the peptide-resin with 10% DIEA in DMF (1 x 1 min), the formyl group on the side of the chain of Trp was removed by treatment with a solution of 15% ethanolamine/ 15% water/ 70% DMF for 2 x 30 min. The partially-deprotected peptide-resin was washed with DMF and DCM and dried under reduced pressure. The final cleavage was done by stirring the peptide-resin in 10 ml of HF containing 1 ml of anisole and dithiothreitol (24 mg) at 0 °C for about 75 min. HF was removed with a flow of nitrogen. The residue was washed with ether (6 x 10 ml) and extracted with 4N HOAc (6 x 10 ml).

The peptide mixture in the aqueous extract was purified on a reverse-phase preparative high pressure liquid chromatography (HPLC) using a reverse phase VYDAC® C₁₈ column (Nest Group, Southborough, MA). The column was eluted with a linear gradient (20% to 50% of solution B over 105 min) at a flow rate of 10

-23-

ml/min (Solution A = water containing 0.1% TFA; Solution B = acetonitrile containing 0.1% of TFA). Fractions were collected and checked on analytical HPLC. Those containing pure product were combined and lyophilized to dryness. 92 mg of a white solid was obtained. Purity was >99% based on analytical HPLC analysis. Electro-spray mass spectrometer analysis gave the molecular weight at 3324.2 (the calculated molecular weight is 3323.7).

The synthesis of other compounds of the present invention can be carried out in the same manner as described for the synthesis of [Aib⁸, A6c³²]hGLP-1(7-36)NH₂ (SEQ ID NO: 114) in Example 52 above but using the appropriate protected amino acids depending on the desired peptide.

[(N^α-HEPES-His)⁷]hGLP-1(7-36)NH₂ (SEQ ID NO: 152) {HEPES is (4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid)} can be synthesized as follows: After assembly of the peptide long chain on MBHA resin (0.20 mmol), the peptide-resin is treated with 100% TFA (2 x 2 min.) and washed with DMF and DCM. The resin is then neutralized with 10% DIEA in DMF for about 2 min. After washing with DMF and DCM, the resin is treated with 0.23 mmol of 2-chloro-1-ethanesulfonyl chloride and 0.7 mmol of DIEA in DMF for about 1 hour. The resin is washed with DMF and DCM and treated with 1.2 mmol of 2-hydroxyethylpiperazine for about 2 hours. The resin is washed with DMF and DCM and treated with different reagents ((1) 20% mercaptoethanol / 10% DIEA in DMF and (2) 15% ethanolamine / 15% water / 70% DMF) to remove the DNP group from the His side chain and formyl group on the Trp side chain as described above before the final HF cleavage of the peptide from the resin.

[(N^α-HEPA-His)⁷]hGLP-1(7-36)NH₂ (SEQ ID NO: 153) ([4-(2-hydroxyethyl)-1-piperazineacetyl]-His⁷]hGLP-1(7-36)NH₂) can be made substantially according to the procedure described immediately above for making [(N^α-HEPES-His)⁷]hGLP-1(7-36)NH₂ (SEQ ID NO: 152) except that 2-bromo-acetic anhydride is used in place of 2-chloro-1-ethanesulfonyl chloride.

Examples 53-90 and 104

Examples 53-90 and 104 were made substantially according to Example 52 but using the appropriate protected amino acid.

Example 53: [A6c^{20,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO:115); MS =3322.3 ; Calc. MW = 3321.7.

- Example 54: [Aib⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 116); MS = 3311.7; Calc. MW = 3311.7.
- Example 55: [(Tma-His)⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 117); MS = 3395.9; Calc. MW = 3396.9.
- 5 Example 56: [A6c⁸]hGLP-1(8-36)-NH₂ (SEQ ID NO: 118); MS = 3214.5; Calc. MW = 3214.7.
- Example 57: [A6c⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 119); MS = 3351.5; Calc. MW = 3351.8.
- Example 58: [A6c^{16,20}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 120); MS = 3335.9; Calc. MW = 3335.8.
- 10 Example 59: [A6c^{29,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 121); MS = 3321.7; Calc. MW = 3321.7.
- Example 60: [A6c²⁰, Aib²⁴]hGLP-1(7-36)-NH₂ (SEQ ID NO: 122); MS = 3323.6; Calc. MW = 3323.7.
- 15 Example 61: [Aib²⁴, A6c^{29,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 123); MS = 3335.7; Calc. MW = 3335.8.
- Example 62: [A6c^{16,29,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 124); MS = 3347.7; Calc. MW = 3347.8.
- Example 63: [Ura⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 125); MS = 3279.5; Calc. MW = 3280.7.
- 20 Example 64: [Paa⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 126); MS = 3290.9; Calc. MW = 3291.8.
- Example 65: [Pta⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 127); MS = 3311.2; Calc. MW = 3311.8.
- 25 Example 66: [N-Me-Ala⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 128); MS = 3311.4; Calc. MW = 3311.7.
- Example 67: [N-Me-D-Ala⁸]hGLP-1(7-36)-NH₂; MS = 3311.6; Calc. MW = 3311.7.
- Example 68: [N-Me-D-Ala⁸]hGLP-1(8-36)-NH₂; MS = 3174.0; Calc. MW = 3174.6.
- Example 69: [N-Me-Gly⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 129); MS = 3297.3; Calc. MW = 3297.7.
- 30 Example 70: [A5c⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 130); MS = 3337.3; Calc. MW = 3337.8.
- Example 71: [N-Me-Glu⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 131); MS = 3311.4; Calc. MW = 3311.7.

- Example 72: [A5c⁸, A6c^{20,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 132); MS = 3361.4;
Calc. MW = 3361.8.
- Example 73: [Aib⁸, A6c³²]hGLP-1(7-36)-NH₂ (SEQ ID NO: 133); MS = 3323.2;
Calc. MW = 3323.7.
- 5 Example 74: [Aib^{8,25}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 134); MS = 3325.8; Calc.
MW = 3325.7.
- Example 75: [Aib^{8,24}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 135); MS = 3325.8; Calc.
MW = 3325.7.
- Example 76: [Aib^{8,30}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 136); MS = 3326.1; Calc.
10 MW = 3325.7.
- Example 77: [Aib⁸, Cha²⁰]hGLP-1(7-36)-NH₂ (SEQ ID NO: 137); MS = 3351.8;
Calc. MW = 3351.8.
- Example 78: [Aib⁸, Cha³²]hGLP-1(7-36)-NH₂ (SEQ ID NO: 138); MS = 3352.0;
Calc. MW = 3351.8.
- 15 Example 79: [Aib⁸, Glu²³]hGLP-1(7-36)-NH₂ (SEQ ID NO: 139); MS = 3311.7;
Calc. MW = 3312.7.
- Example 80: [Aib⁸, A6c²⁰]hGLP-1(7-36)-NH₂ (SEQ ID NO: 140); MS = 3323.6;
Calc. MW = 3323.7.
- Example 81: [Aib⁸, A6c^{20,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 141); MS = 3335.3;
20 Calc. MW = 3335.7.
- Example 82: [Aib^{8,22}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 142); MS = 3339.8; Calc.
MW = 3339.8.
- Example 83: [Aib⁸, β-Ala²²]hGLP-1(7-36)-NH₂ (SEQ ID NO: 143); MS = 3325.6;
Calc. MW = 3325.8.
- 25 Example 84: [Aib⁸, Lys²⁵]hGLP-1(7-36)-NH₂ (SEQ ID NO: 144); MS = 3369.0;
Calc. MW = 3368.8.
- Example 85: [Aib⁸, A6c¹²]hGLP-1(7-36)-NH₂ (SEQ ID NO: 145); MS = 3289.8;
Calc. MW = 3289.7.
- Example 86: [Aib⁸, A6c²⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 146); MS = 3323.9;
30 Calc. MW = 3323.7.
- Example 87: [Aib⁸, A6c³³]hGLP-1(7-36)-NH₂ (SEQ ID NO: 147); MS = 3338.0;
Calc. MW = 3337.8.
- Example 88: [Aib^{8,14}]hGLP-1(7-36)NH₂ (SEQ ID NO: 148); MS = 3309.8; Calc.
MW = 3309.7.

-26-

Example 89: [Aib^{8,18}]hGLP-1(7-36)NH₂ (SEQ ID NO: 149); MS = 3309.7; Calc. MW = 3309.7.

Example 90: [Aib^{8,17}]hGLP-1(7-36)NH₂ (SEQ ID NO: 150); MS = 3309.4; Calc. MW = 3309.7.

5 Example 104: [Aib⁸, D-Arg;²⁶]hGLP-1(7-36)NH₂; MS = 3310.7; Calc. MW = 3311.73.

Example 91

[Aib⁸, A5c³³]hGLP-1 (7-36)NH₂ (SEQ ID NO: 154)

The title compound can be made substantially according to Example 52
10 using the appropriate protected amino acids.

Example 92

[Aib⁸, A6c³², Lys³⁶(N^ε-tetradecanoyl)]hGLP-1(7-36)NH₂ (SEQ ID NO: 155)

The Boc amino acids to be used are the same as those in the synthesis of [Aib⁸, A6c³²]hGLP-1(7-36)NH₂ (SEQ ID NO: 114) (Example 52) except that Fmoc-
15 Lys(Boc)-OH is used here for the Lys³⁶(N^ε-tetradecanoyl) residue. The first amino acid residue is coupled to the resin manually on a shaker. 2.5 mmol of Fmoc-Lys(Boc)-OH is dissolved in 4 ml of 0.5N HBTU in DMF. To the solution is added 1 ml of DIEA. The mixture is shaken for about 2 min. To the solution is then added 0.2 mmol of MBHA resin (substitution = 0.91 mmol/g). The mixture is shaken for
20 about 1 hr. The resin is washed with DMF and treated with 100% TFA for 2x2 min to remove the Boc protecting group. The resin is washed with DMF. Myristic acid (2.5 mmol) is pre-activated with HBTU (2.0 mmol) and DIEA (1.0 ml) in 4 ml of DMF for 2 min and is coupled to the Fmoc-Lys-resin. The coupling time is about 1 hr. The resin is washed with DMF and treated with 25% piperidine in DMF for 2x20 min to
25 remove the Fmoc protecting group. The resin is washed with DMF and transferred to the reaction vessel of the peptide synthesizer. The remainder of the synthesis and purification procedures of the peptide are the same as those in the synthesis of [Aib⁸, A6c³²]hGLP-1(7-36)NH₂. (SEQ ID NO: 114)

The syntheses of other compounds containing Lys(N^ε-alkanoyl) residue are
30 carried out in an analogous manner as described for the synthesis of [Aib⁸, A6c³², Lys³⁶(N^ε-tetradecanoyl)]hGLP-1(7-36)NH₂ SEQ ID NO: 155). Fmoc-Lys(Boc)-OH amino acid is used for the residue of Lys(N^ε-alkanoyl) in the peptide, while Boc-Lys(2ClZ)-OH amino acid is used for the residue of Lys. If the Lys(N^ε-alkanoyl)

-27-

residue is not at the C-terminus, the peptide fragment immediately prior to the Lys(N^ε-alkanoyl) residue is assembled on the resin on the peptide synthesizer first.

Examples 93-98

Examples 93-98 can be made substantially according to the procedure described for Example 92 using the appropriate amino acids.

Example 93: [Aib⁸, A6c³², Lys³⁶(N^ε-tetradecanoyl)]hGLP-1(7-36)NH₂ (SEQ ID NO: 155)

Example 94: [Aib⁸, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl)]hGLP-1(7-36)NH₂ (SEQ ID NO: 156)

Example 95: [Aib⁸, Arg²⁶, A6c³², Lys³⁴(N^ε-tetradecanoyl)]hGLP-1(7-36)NH₂ (SEQ ID NO: 157)

Example 96: [Aib⁸, Lys²⁶(N^ε-tetradecanoyl), A6c³², Arg³⁴]hGLP-1(7-36)NH₂ (SEQ ID NO: 158)

Example 97: [Aib⁸, Lys³⁶(N^ε-octanoyl)]hGLP-1 (7-36)NH₂ (SEQ ID NO: 159)

Example 98: [Aib⁸, A6c^{20,32}, Lys³⁶(N^ε-octanoyl)]hGLP-1 (7-36)NH₂ (SEQ ID NO: 160)

Example 99

[Aib⁸, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl)]hGLP-1(7-36)-OH (SEQ ID NO: 161)

The Boc amino acids to be used are the same as those used in the synthesis of [Aib⁸, A6c³², Lys³⁶(N^ε-tetradecanoyl)]hGLP-1(7-36)NH₂ (SEQ ID NO: 162) (Example 92). Fmoc-Lys(Boc)-OH (2.5 mmol) is pre-activated with HBTU (2.0 mmol), HOBt (2.0 mmol) and DIEA (2.5 ml) in DMF (4 ml) for about 2 min. This amino acid is coupled to 235 mg of PAM resin (Chem-Impex, Wood Dale, IL; substitution = 0.85 mmol/g) manually on a shaker. The coupling time is about 8 hrs. The remainder of the synthesis and purification procedures for making the peptide are the same as those described in Example 52.

The syntheses of other analogs of hGLP-1(7-36)-OH (SEQ ID NO: 3) and hGLP-1(7-37)-OH, (SEQ ID NO: 4) which contain Lys(N^ε-alkanoyl) residue, are carried out in an analogous manner as described for the synthesis of [Aib⁸, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl)]hGLP-1(7-36)-OH (SEQ ID NO: 161). Fmoc-Lys(Boc)-OH amino acid is used for the residue of Lys(N^ε-alkanoyl) in the peptide, while Boc-Lys(2CIZ)-OH amino acid is used for the residue of Lys.

Examples 100-103

Examples 100-103 can be made substantially according to the procedure described for Example 99 using the appropriate amino acids.

- 5 Example 100: [Aib⁸, Arg²⁶, A6c³², Lys³⁴(N^ε-tetradecanoyl)]hGLP-1(7-36)-OH (SEQ ID NO: 162)
- Example 101: [Aib⁸, Lys²⁶(N^ε-tetradecanoyl), A6c³², Arg³⁴]hGLP-1(7-36)-OH (SEQ ID NO: 163)
- Example 102: [Aib⁸, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl)]hGLP-1(7-37)-OH (SEQ ID NO: 164)
- 10 Example 103: [Aib⁸, Arg²⁶, A6c³², Lys³⁴(N^ε-tetradecanoyl)]hGLP-1(7-37)-OH (SEQ ID NO: 165)

CLAIMS

What is claimed is:

1. A compound of formula (I),
- 5 (R²R³)-A⁷-A⁸-A⁹-A¹⁰-A¹¹-A¹²-A¹³-A¹⁴-A¹⁵-A¹⁶-A¹⁷-A¹⁸-A¹⁹-A²⁰-A²¹-A²²-A²³-
A²⁴-A²⁵-A²⁶-A²⁷-A²⁸-A²⁹-A³⁰-A³¹-A³²-A³³-A³⁴-A³⁵-A³⁶-A³⁷-R¹,
- (I)
- wherein
- A⁷ is L-His, Ura, Paa, Pta, D-His, Tyr, 3-Pal, 4-Pal, Hppa, Tma-His, Amp or deleted,
- 10 provided that when A⁷ is Ura, Paa, Pta or Hppa then R² and R³ are deleted;
- A⁸ is Ala, D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala, Arg or N-Me-Gly;
- A⁹ is Glu, N-Me-Glu, N-Me-Asp or Asp;
- A¹⁰ is Gly, Acc, Ala, D-Ala, Phe or Aib;
- A¹¹ is Thr or Ser;
- 15 A¹² is Phe, Acc, Aic, Aib, 3-Pal, 4-Pal, β-Nal, Cha, Trp or X¹-Phe;
- A¹³ is Thr or Ser;
- A¹⁴ is Ser, Thr, Ala or Aib;
- A¹⁵ is Asp, Ala, D-Asp or Glu;
- A¹⁶ is Val, D-Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala, D-Ala, Tba or Cha;
- 20 A¹⁷ is Ser, Ala, D-Ala, Aib, Acc or Thr;
- A¹⁸ is Ser, Ala, D-Ala, Aib, Acc or Thr;
- A¹⁹ is Tyr, D-Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β-Nal, Amp or X¹-Phe;
- A²⁰ is Leu, Ala, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X¹-Phe;
- A²¹ is Glu, Ala or Asp;
- 25 A²² is Gly, Acc, Ala, D-Ala, β-Ala or Aib;
- A²³ is Gln, Asp, Ala, D-Ala, Aib, Acc, Asn or Glu;
- A²⁴ is Ala, Aib, Val, Abu, Tle or Acc;
- A²⁵ is Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-NR¹⁰R¹¹)-C(O) or HN-CH((CH₂)₆-X³)-C(O);
- 30 A²⁶ is Lys, Ala, 3-Pal, 4-Pal, Arg, hArg, Orn, Amp, HN-CH((CH₂)_n-NR¹⁰R¹¹)-C(O) or HN-CH((CH₂)₆-X³)-C(O);
- A²⁷ is Glu, Ala, D-Ala or Asp;
- A²⁸ is Phe, Ala, Pal, β-Nal, X¹-Phe, Aic, Acc, Aib, Cha or Trp;

-30-

A²⁹ is Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala, Tba or Phe;

A³⁰ is Ala, Aib, Acc or deleted;

A³¹ is Trp, Ala, β-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib, Cha, Amp or deleted;

A³² is Leu, Ala, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X¹-Phe, Ala or deleted;

5 A³³ is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, X¹-Phe, Tba, Gaba or deleted;

A³⁴ is Lys, Arg, hArg, Orn, Amp, Gaba, HN-CH((CH₂)_n-NR¹⁰R¹¹)-C(O), HN-CH((CH₂)₆-X³)-C(O) or deleted;


A³⁵ is Gly or deleted;

10 A³⁶ is L- or D-Arg, D- or L-Lys, D- or L-hArg, D- or L-Orn, Amp, HN-CH((CH₂)_n-NR¹⁰R¹¹)-C(O), HN-CH((CH₂)₆-X³)-C(O) or deleted;

A³⁷ is Gly or deleted;

X¹ for each occurrence is independently selected from the group consisting of (C₁-C₆)alkyl, OH and halo;


15 R¹ is OH, NH₂, (C₁-C₁₂)alkoxy, or NH-X²-CH₂-Z⁰, wherein X² is a (C₁-C₁₂)hydrocarbon moiety, and Z⁰ is H, OH, CO₂H or CONH₂;



X³ is or -C(O)-NHR¹², wherein X⁴ for each occurrence is independently -C(O)-, -NH-C(O)- or -CH₂-, and f for each occurrence is independently an integer from 1 to 29;

20 each of R² and R³ is independently selected from the group consisting of H, (C₁-C₃₀)alkyl, (C₂-C₃₀)alkenyl, phenyl(C₁-C₃₀)alkyl, naphthyl(C₁-C₃₀)alkyl, hydroxy(C₁-C₃₀)alkyl, hydroxy(C₂-C₃₀)alkenyl, hydroxyphenyl(C₁-C₃₀)alkyl, and hydroxynaphthyl(C₁-C₃₀)alkyl; or one of R² and R³ is C(O)X⁵ in which X⁵ is (C₁-C₃₀)alkyl, (C₂-C₃₀)alkenyl, phenyl(C₁-C₃₀)alkyl, naphthyl(C₁-C₃₀)alkyl, hydroxy(C₁-C₃₀)alkyl, hydroxy(C₂-C₃₀)alkenyl, hydroxyphenyl(C₁-C₃₀)alkyl,

25 hydroxynaphthyl(C₁-C₃₀)alkyl, (CH₃)₂-N-C⁺=N(CH₃)₂.




-31-

where Y is H or OH, r is 0 to 4 and q is 0 to 4;


e for each occurrence is independently an integer from 1 to 4;

n for each occurrence is independently an integer from 1-5; and

R¹⁰ and R¹¹ for each occurrence is each independently H, (C₁-C₃₀)alkyl, (C₁-C₃₀)acyl, (C₁-C₃₀)alkylsulfonyl, -C((NH)(NH₂)) or



, provided that when R¹⁰ is (C₁-C₃₀)acyl,



(C₁-C₃₀)alkylsulfonyl, -C((NH)(NH₂)) or

R¹¹ is H or (C₁-C₃₀)alkyl; and

R¹² is (C₁-C₃₀)alkyl;

10 with the proviso that:

(i) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1(7-36, or -37)NH₂ (SEQ ID NOS: 1, 2) or hGLP-1(7-36, or -37)OH (SEQ ID NOS: 3, 4);

(ii) a compound of formula (I) is not an analogue of hGLP-1(7-36, or -37)NH₂ (SEQ ID NOS: 1,2) or hGLP-1(7-36, or -37)OH (SEQ ID NOS: 3, 4) wherein a single position has been substituted by Ala;

(iii) a compound of formula (I) is not [Lys²⁶(N^ε-alkanoyl)]hGLP-1(7-36, or -37)-E (SEQ ID NOS: 5-8), [Lys³⁴(N^ε-alkanoyl)]hGLP-1(7-36, or -37)-E (SEQ ID NOS: 9-12), [Lys^{26,34}-bis(N^ε-alkanoyl)]hGLP-1(7-36, or -37)-E (SEQ ID NOS: 13-16), [Arg²⁶, Lys³⁴(N^ε-alkanoyl)]hGLP-1(8-36, or -37)-E (SEQ ID NOS: 17-20), or [Arg^{26,34}, Lys³⁶(N^ε-alkanoyl)]hGLP-1(7-36, or -37)-E, wherein E is -OH or -NH₂ (SEQ ID NOS: 21-24);


(iv) a compound of formula (I) is not Z¹-hGLP-1(7-36, or -37)-OH, Z¹-hGLP-1(7-36, or -37)-NH₂, where Z¹ is selected from the group consisting of

25 (a) [Arg²⁶] (SEQ ID NOS: 25-28), [Arg³⁴] (SEQ ID NOS: 29-32), [Arg^{26,34}] (SEQ ID NOS: 33-36), [Lys³⁶] (SEQ ID NOS: 37-40), [Arg²⁶, Lys³⁶] (SEQ ID NOS: 41-44), [Arg³⁴, Lys³⁶] (SEQ ID NOS: 45-46), [D-Lys³⁶], [Arg³⁶] (SEQ ID NOS: 37-40), [D-Arg³⁶], [Arg^{26,34}, Lys³⁶] (SEQ ID NOS: 49-52), or [Arg^{26,36}, Lys³⁴] (SEQ ID NOS: 25-28);


30 (b) [Asp²¹] (SEQ ID NOS: 53-56);

-32-

- (c) at least one of [Aib⁶] (SEQ ID NOS: 57-60), [D-Ala⁸] and [Asp⁹] (SEQ ID NOS: 61-64); and
- (d) [Tyr⁷] (SEQ ID NOS: 65-68), [N-acyl-His⁷] (SEQ ID NOS: 69-72), [N-alkyl-His⁷] (SEQ ID NOS: 73-76), [N-acyl-D-His⁷] or [N-alkyl-D-His⁷];
- 5 (v) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (a) to (d); and
- (vi) a compound of formula (I) is not [N-Me-Ala⁸]hGLP-1(8-36 or -37) (SEQ ID NOS: 77, 78), [Glu¹⁵]hGLP-1(7-36 or -37) (SEQ ID NOS: 79, 80), [Asp²¹]hGLP-1(7-36 or -37) (SEQ ID NOS: 53, 54) or [Phe³¹]hGLP-1(7-36 or -37) (SEQ ID NOS: 81, 82).
- 10 2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein A¹¹ is Thr; A¹³ is Thr; A¹⁴ is Ser, Aib or Ala; A¹⁷ is Ser, Ala, Aib or D-Ala; A¹⁸ is Ser, Ala, Aib or D-Ala; A²¹ is Glu or Ala; A²³ is Gln, Glu, or Ala; and A²⁷ is Glu or Ala.
3. A compound according to claim 2 or a pharmaceutically acceptable salt thereof wherein A⁹ is Glu, N-Me-Glu or N-Me-Asp; A¹² is Phe, Acc or Aic; A¹⁶ is Val, D-Val, Acc, Aib, Ala, Tle or D-Ala; A¹⁹ is Tyr, 3-Pal, 4-Pal or D-Tyr; A²⁰ is Leu, Acc, Cha, Ala or Tle; A²⁴ is Ala, Aib or Acc; A²⁵ is Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-NH-R¹⁰)-C(O); A²⁸ is Phe or Ala; A²⁹ is Ile, Acc or Tle; A³⁰ is Ala, Aib or deleted; A³¹ is Trp, Ala, 3-Pal, 4-Pal or deleted; A³² is Leu, Acc, Cha, Ala or deleted; A³³ is Val, Acc, Ala, Gaba, Tle or deleted.
- 15 4. A compound according to claim 3 or a pharmaceutically acceptable salt thereof wherein A⁸ is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A¹⁰ is Gly, Ala, D-Ala or Phe; A¹² is Phe, A6c or A5c; A¹⁶ is Val, Ala, Tle, A6c, A5c or D-Val; A²⁰ is Leu, A6c, A5c, Cha, Ala or Tle; A²² is Gly, Aib, β-Ala, L-Ala or D-Ala; A²⁴ is Ala or Aib; A²⁹ is Ile, A6c, A5c or Tle; A³² is Leu, A6c, A5c, Cha, Ala or deleted; A³³ is Val, A6c, A5c, Ala, Gaba, Tle or deleted.
- 25 5. A compound according to claim 4 or a pharmaceutically acceptable salt thereof wherein R¹ is OH or NH₂.
6. A compound according to claim 5 or a pharmaceutically acceptable salt thereof wherein R² is H and R³ is (C₁-C₃₀)alkyl, (C₂-C₃₀)alkenyl, (C₁-C₃₀)acyl,
- 30



-33-



7. A compound according to claim 1 wherein said compound is
- [D-Ala⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]-GLP-1(7-34)NH₂;
 [D-Ala^{8,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂;
- 5 [Ala^{18,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 83);
 [Ala^{16,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 84);
 [Ala^{14,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 85);
 [Ala^{22,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 86);
 [Hppa⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 87);
- 10 [Ala^{15,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 88);
 [Ala^{17,23,27}, 3-Pal^{19,31}]hGLP-1(7-35)-NH₂ (SEQ ID NO: 89);
 [Ala^{22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 90);
 [Ala^{15,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 91);
 [Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 92);
- 15 [Ala^{18,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 93);
 [Ala^{21,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 94);
 [Ala^{22,23,26,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 95);
 [Ala^{22,23,27,32}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 96);
 [Ala^{22,23,26,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 97);
- 20 [Ala^{22,23,27,31}, 3-Pal¹⁹, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 98);
 [Ala^{22,23,27,28}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 99);
 [Ala^{22,23,27,29}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 100);
 [Ala^{23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 101);
 [Ala^{20,22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 102);
- 25 [Ala^{22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 103);
 [Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂ (SEQ ID NO: 104);
 [D-Ala¹⁰, Ala^{22,23,27}, 3-Pal^{19,31}, Gaba³³]hGLP-1(7-33)-NH₂;
 [D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}]hGLP-1(7-34)-NH₂;
 [Ala^{17,23,27}, 3-Pal^{19,28,31}]hGLP-1(7-34)-NH₂ (SEQ ID NO: 105);
- 30 [D-Ala⁸, Ala¹⁷, 3-Pal^{19,31}]hGLP-1(7-34)-NH₂;
 [Ala^{17,23,27}, 3-Pal^{19,31}]hGLP-1(7-34)-NH₂ (SEQ ID NO: 106);
 [D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Tle²⁹]hGLP-1(7-34)-NH₂;

-34-

- [D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Tie¹⁶]hGLP-1(7-34)-NH₂;
 [D-Ala⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂;
 [D-Ala²², Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂;
 [Aib⁸, Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 107);
 5 [D-Ala⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂;
 [Aib⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂ (SEQ ID NO: 108);
 [Ala^{17,18,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 109);
 [Ala^{17,23,27}, 3-Pal^{19,31}, Tie³³, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 110);
 [Tie¹⁶, Ala^{17,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 111);
 10 [N-Me-D-Ala⁸, Ala^{17,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂;
 [Aib⁸, Ala^{17,18,22,23,27}, 3-Pal^{19,31}]hGLP-1(7-33)-NH₂ (SEQ ID NO: 112);
 [Ala^{17,18,22,23,27}, 3-Pal^{19,31}, Tie^{18,20}, Gaba³⁴]hGLP-1(7-34)-NH₂ (SEQ ID NO: 113);
 [D-Ala⁸, Ala^{17,18,22,23,27}, 3-Pal^{19,31}, Tie¹⁶, Gaba³⁴]hGLP-1(7-34)-NH₂;
 [D-Ala^{8,22}, Ala^{17,18,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂;
 15 [D-Ala^{8,18}, Ala^{17,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂;
 [D-Ala^{8,17}, Ala^{18,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; or
 [D-Ala⁸, Ala^{17,18,22,23,27}, 3-Pal^{19,31}, Gaba³⁴]hGLP-1(7-34)-NH₂; or a pharmaceutically acceptable salt thereof.
8. A compound according to claim 1 wherein said compound is
- 20 [Aib⁸, A6c³²]hGLP-1(7-36)NH₂ (SEQ ID NO: 114);
 [A6c^{20,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 115);
 [Aib⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 116);
 [(Tma-His)⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 117);
 [A6c⁸]hGLP-1(8-36)-NH₂ (SEQ ID NO: 118);
 25 [A6c⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 119);
 [A6c^{16,20}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 120);
 [A6c^{29,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 121);
 [A6c²⁰, Aib²⁴]hGLP-1(7-36)-NH₂ (SEQ ID NO: 122);
 [Aib²⁴, A6c^{29,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 123);
 30 [A6c^{16,29,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 124);
 [Ura⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 125);
 [Paa⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 126);
 [Pta⁷]hGLP-1(7-36)-NH₂ (SEQ ID NO: 127);
 [N-Me-Ala⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 128);

-35-

- [N-Me-Ala⁸]hGLP-1(8-36)-NH₂ (SEQ ID NO:);
 [N-Me-D-Ala⁸]hGLP-1(7-36)-NH₂;
 [N-Me-D-Ala⁸]hGLP-1(8-36)-NH₂;
 [N-Me-Gly⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 129);
 5 [A5c⁸]hGLP-1(7-36)-NH₂ (SEQ ID NO: 130) ;
 [N-Me-Glu⁹]hGLP-1(7-36)-NH₂ (SEQ ID NO: 131);
 [A5c⁸, A6c^{20,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 132);
 [Aib⁸, A6c³²]hGLP-1(7-36)-NH₂ (SEQ ID NO: 133);
 [Aib^{8,25}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 134);
 10 [Aib^{8,24}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 135);
 [Aib^{8,30}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 136);
 [Aib⁸, Cha²⁰]hGLP-1(7-36)-NH₂ (SEQ ID NO: 137);
 [Aib⁸, Cha³²]hGLP-1(7-36)-NH₂ (SEQ ID NO: 138);
 [Aib⁸, Glu²³]hGLP-1(7-36)-NH₂ (SEQ ID NO: 139);
 15 [Aib⁸, A6c²⁰]hGLP-1(7-36)-NH₂ (SEQ ID NO: 140);
 [Aib⁸, A6c^{20,32}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 141);
 [Aib^{8,22}]hGLP-1(7-36)-NH₂ (SEQ ID NO: 142);
 [Aib⁸, β-Ala²²]hGLP-1(7-36)-NH₂ (SEQ ID NO: 143);
 [Aib⁸, Lys²⁵]hGLP-1(7-36)-NH₂ (SEQ ID NO: 144);
 20 [Aib⁸, A6c¹²]hGLP-1(7-36)-NH₂ (SEQ ID NO: 145);
 [Aib⁸, A6c²⁹]hGLP-1(7-36)-NH₂ (SEQ ID NO: 146);
 [Aib⁸, A6c³³]hGLP-1(7-36)-NH₂ (SEQ ID NO: 147);
 [Aib^{8,14}]hGLP-1(7-36)NH₂ (SEQ ID NO: 148);
 [Aib^{8,18}]hGLP-1(7-36)NH₂ (SEQ ID NO: 149);
 25 [Aib^{8,17}]hGLP-1(7-36)NH₂ (SEQ ID NO: 150); or
 [Aib⁸, D-Arg²⁶]hGLP-1(7-36)NH₂; or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
- 30 10. A method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

11. A method of treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis, neurodegenerative disease, renal failure, congestive heart
5 failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension, in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

12. A method according to claim 11 wherein said disease is Type I
10 diabetes or Type II diabetes.

INTERNATIONAL SEARCH REPORT

national Application No
PCT/US 99/28929

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K14/605 A61K38/26 A61P3/08				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K A61K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	WO 91 11457 A (BUCKLEY DOUGLAS I ;HABENER JOEL F (US); MALLORY JOANNE B (US); MOJ) 8 August 1991 (1991-08-08) claims; examples	1,2,9-12		
X	EP 0 733 644 A (LILLY CO ELI) 25 September 1996 (1996-09-25) page 3, line 51 -page 4, line 1; claims; examples	1,2,9-12		
X	WO 97 29180 A (BRODERICK CAROL L ;BORTS TRACY L (US); MILLER ANNE R (US); LILLY C) 14 August 1997 (1997-08-14) claims; examples	1,2,9-12		
X	US 5 545 618 A (BUCKLEY DOUGLAS I ET AL) 13 August 1996 (1996-08-13) claims; figures 1,2A; examples	1,2,9-12		
-/-				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.				
<input checked="" type="checkbox"/> Patent family members are listed in annex.				
* Special categories of cited documents :				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Z" document member of the same patent family </td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Z" document member of the same patent family
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Z" document member of the same patent family			
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">8 May 2000</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">15/05/2000</div>		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Fuhr, C</div>		

INTERNATIONAL SEARCH REPORT

national Application No
PCT/US 99/28929

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	FR 2 777 283 A (ADIR) 15 October 1999 (1999-10-15) page 2, line 10 -page 6, line 3; claims; examples	1, 2, 9-12
A	WO 98 08871 A (NOVONORDISK AS ; KNUDSEN LISELOTTE BJERRE (DK); NIELSEN PER FRANKLI) 5 March 1998 (1998-03-05) claims; examples	1, 9-12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 28929

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 10-12 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/28929

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9111457 A	08-08-1991	AT 164852 T	15-04-1998
		CA 2073856 A	25-07-1991
		DE 69129226 D	14-05-1998
		DE 69129226 T	30-07-1998
		DK 512042 T	11-05-1998
		EP 0512042 A	11-11-1992
		ES 2113879 T	16-05-1998
		US 5545618 A	13-08-1996
EP 0733644 A	25-09-1996	US 5705483 A	06-01-1998
		AU 708159 B	29-07-1999
		AU 2026895 A	03-10-1996
		BR 9503036 A	23-09-1997
		CA 2150080 A	22-09-1996
		CN 1131674 A	25-09-1996
		CZ 9501321 A	16-10-1996
		FI 952536 A	22-09-1996
		HU 74729 A	28-02-1997
		JP 8269097 A	15-10-1996
		NO 952034 A	23-09-1996
		NZ 272186 A	29-01-1997
		PL 308783 A	30-09-1996
		US 5977071 A	02-11-1999
		ZA 9504141 A	22-11-1996
WO 9729180 A	14-08-1997	AU 2263197 A	28-08-1997
		CA 2243718 A	14-08-1997
		EP 0879279 A	25-11-1998
US 5545618 A	13-08-1996	AT 164852 T	15-04-1998
		CA 2073856 A	25-07-1991
		DE 69129226 D	14-05-1998
		DE 69129226 T	30-07-1998
		DK 512042 T	11-05-1998
		EP 0512042 A	11-11-1992
		ES 2113879 T	16-05-1998
		WO 9111457 A	08-08-1991
FR 2777283 A	15-10-1999	AU 2368899 A	21-10-1999
		CN 1232038 A	20-10-1999
		EP 0955314 A	10-11-1999
		HU 9900604 A	28-09-1999
		JP 11310597 A	09-11-1999
		NO 991199 A	11-10-1999
		NZ 334379 A	28-10-1999
		PL 331960 A	11-10-1999
WO 9808871 A	05-03-1998	AU 3847897 A	19-03-1998
		AU 4112497 A	19-03-1998
		CN 1232470 A	20-10-1999
		CZ 9900629 A	14-07-1999
		WO 9808872 A	05-03-1998
		EP 0944648 A	29-09-1999
		EP 0929576 A	21-07-1999
		JP 2000500505 T	18-01-2000
		NO 990950 A	28-04-1999
		PL 331896 A	16-08-1999

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)